Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia
IntroductionHypertriglyceridemia is the most prevalent dyslipidemia in patients with chronic kidney disease (CKD). However, research about fibrate treatment in CKD patients is limited, and assessing its benefits becomes challenging due to the frequent concurrent use of statins. Thus, this study is a...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1333553/full |
| _version_ | 1827352770480439296 |
|---|---|
| author | Chieh-Li Yen Chieh-Li Yen Pei-Chun Fan Pei-Chun Fan Cheng-Chia Lee Cheng-Chia Lee Jia-Jin Chen Jia-Jin Chen Chao-Yu Chen Chao-Yu Chen Yi-Ran Tu Yi-Ran Tu Pao-Hsien Chu Pao-Hsien Chu Ching-Chung Hsiao Ching-Chung Hsiao Yung-Chang Chen Yung-Chang Chen Chih-Hsiang Chang Chih-Hsiang Chang |
| author_facet | Chieh-Li Yen Chieh-Li Yen Pei-Chun Fan Pei-Chun Fan Cheng-Chia Lee Cheng-Chia Lee Jia-Jin Chen Jia-Jin Chen Chao-Yu Chen Chao-Yu Chen Yi-Ran Tu Yi-Ran Tu Pao-Hsien Chu Pao-Hsien Chu Ching-Chung Hsiao Ching-Chung Hsiao Yung-Chang Chen Yung-Chang Chen Chih-Hsiang Chang Chih-Hsiang Chang |
| author_sort | Chieh-Li Yen |
| collection | DOAJ |
| description | IntroductionHypertriglyceridemia is the most prevalent dyslipidemia in patients with chronic kidney disease (CKD). However, research about fibrate treatment in CKD patients is limited, and assessing its benefits becomes challenging due to the frequent concurrent use of statins. Thus, this study is aimed to investigate the role of fibrate in CKD stage 3 patients with hypertriglyceridemia who did not receive other lipid-lowering agents.MethodsThis study enrolled patients newly diagnosed CKD3 with LDL-C<100mg/dL and had never received statin or other lipid-lowering agents from Chang Gung Research Database. The participants were categorized into 2 groups based on the use of fibrate: fibrate group and non-fibrate group (triglyceride >200mg/dL but not receiving fibrate treatment). The inverse probability of treatment weighting was performed to balance baseline characteristics.ResultsCompared with the non-fibrate group (n=2020), the fibrate group (n=705) exhibited significantly lower risks of major adverse cardiac and cerebrovascular events (MACCEs) (10.4% vs. 12.8%, hazard ratios [HRs]: 0.69, 95% confidence interval [CI]: 0.50 to 0.95), AMI (2.3% vs. 3.9%, HR: 0.52, 95% CI: 0.37 to 0.73), and ischemic stroke (6.3% vs. 8.0%, HR: 0.67, 95% CI: 0.52 to 0.85). The risk of all-cause mortality (5.1% vs. 4.5%, HR: 1.09, 95% CI: 0.67 to 1.79) and death from CV (2.8% vs. 2.3%, HR: 1.07, 95% CI: 0.29 to 2.33) did not significantly differ between the 2 groups.ConclusionThis study suggests that, in moderate CKD patients with hypertriglyceridemia but LDL-C < 100mg/dL who did not take other lipid-lowering agents, fibrates may be beneficial in reducing cardiovascular events. |
| first_indexed | 2024-03-08T03:11:49Z |
| format | Article |
| id | doaj.art-7c3f3c0fa94147a89d8d94487c6b6439 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-08T03:11:49Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-7c3f3c0fa94147a89d8d94487c6b64392024-02-13T04:40:56ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-02-011510.3389/fendo.2024.13335531333553Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemiaChieh-Li Yen0Chieh-Li Yen1Pei-Chun Fan2Pei-Chun Fan3Cheng-Chia Lee4Cheng-Chia Lee5Jia-Jin Chen6Jia-Jin Chen7Chao-Yu Chen8Chao-Yu Chen9Yi-Ran Tu10Yi-Ran Tu11Pao-Hsien Chu12Pao-Hsien Chu13Ching-Chung Hsiao14Ching-Chung Hsiao15Yung-Chang Chen16Yung-Chang Chen17Chih-Hsiang Chang18Chih-Hsiang Chang19Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanKidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanKidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanKidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanKidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanKidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanDepartment of Cardiology, Chang Gung Memorial Hospital, Taoyuan, TaiwanKidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanKidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanKidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, TaiwanCollege of Medicine, Chang Gung University, Taoyuan, TaiwanIntroductionHypertriglyceridemia is the most prevalent dyslipidemia in patients with chronic kidney disease (CKD). However, research about fibrate treatment in CKD patients is limited, and assessing its benefits becomes challenging due to the frequent concurrent use of statins. Thus, this study is aimed to investigate the role of fibrate in CKD stage 3 patients with hypertriglyceridemia who did not receive other lipid-lowering agents.MethodsThis study enrolled patients newly diagnosed CKD3 with LDL-C<100mg/dL and had never received statin or other lipid-lowering agents from Chang Gung Research Database. The participants were categorized into 2 groups based on the use of fibrate: fibrate group and non-fibrate group (triglyceride >200mg/dL but not receiving fibrate treatment). The inverse probability of treatment weighting was performed to balance baseline characteristics.ResultsCompared with the non-fibrate group (n=2020), the fibrate group (n=705) exhibited significantly lower risks of major adverse cardiac and cerebrovascular events (MACCEs) (10.4% vs. 12.8%, hazard ratios [HRs]: 0.69, 95% confidence interval [CI]: 0.50 to 0.95), AMI (2.3% vs. 3.9%, HR: 0.52, 95% CI: 0.37 to 0.73), and ischemic stroke (6.3% vs. 8.0%, HR: 0.67, 95% CI: 0.52 to 0.85). The risk of all-cause mortality (5.1% vs. 4.5%, HR: 1.09, 95% CI: 0.67 to 1.79) and death from CV (2.8% vs. 2.3%, HR: 1.07, 95% CI: 0.29 to 2.33) did not significantly differ between the 2 groups.ConclusionThis study suggests that, in moderate CKD patients with hypertriglyceridemia but LDL-C < 100mg/dL who did not take other lipid-lowering agents, fibrates may be beneficial in reducing cardiovascular events.https://www.frontiersin.org/articles/10.3389/fendo.2024.1333553/fullTGchronic kidney diseasehypertriglyceridemiafibrateAMIstroke |
| spellingShingle | Chieh-Li Yen Chieh-Li Yen Pei-Chun Fan Pei-Chun Fan Cheng-Chia Lee Cheng-Chia Lee Jia-Jin Chen Jia-Jin Chen Chao-Yu Chen Chao-Yu Chen Yi-Ran Tu Yi-Ran Tu Pao-Hsien Chu Pao-Hsien Chu Ching-Chung Hsiao Ching-Chung Hsiao Yung-Chang Chen Yung-Chang Chen Chih-Hsiang Chang Chih-Hsiang Chang Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia Frontiers in Endocrinology TG chronic kidney disease hypertriglyceridemia fibrate AMI stroke |
| title | Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia |
| title_full | Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia |
| title_fullStr | Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia |
| title_full_unstemmed | Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia |
| title_short | Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia |
| title_sort | fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia |
| topic | TG chronic kidney disease hypertriglyceridemia fibrate AMI stroke |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1333553/full |
| work_keys_str_mv | AT chiehliyen fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT chiehliyen fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT peichunfan fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT peichunfan fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT chengchialee fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT chengchialee fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT jiajinchen fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT jiajinchen fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT chaoyuchen fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT chaoyuchen fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT yirantu fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT yirantu fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT paohsienchu fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT paohsienchu fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT chingchunghsiao fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT chingchunghsiao fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT yungchangchen fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT yungchangchen fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT chihhsiangchang fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia AT chihhsiangchang fibrateandtheriskofcardiovasculardiseaseamongmoderatechronickidneydiseasepatientswithprimaryhypertriglyceridemia |